Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany
Santhera Pharmaceuticals, today announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement for AGAMREE (vamorolone) for...
Percheron Therapeutics Announces Terminated of ATL1102 Study for DMD
“One way or other, we don’t think ATL-1102 can remain the centerpiece of the story put forward to investors,” Garner told investors in a...
Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201
ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA)...
Sidra Medicine Establishes Gene Therapy Center for Rare Genetic Diseases in Qatar
The announcement was made at Arab Health 2025, where Sidra Medicine will showcase its global patient care initiatives, including flagship services like the Heart...
In Brazil, the Government is Expected to Implement a Risk-Sharing Model with Roche for ELEVIDYS
Elevidys, a treatment for Duchenne muscular dystrophy, is the most costly medication authorized in Brazil and among the most expensive in the world, with...